Allist(SH:688578) Xin Lang Cai Jing·2025-09-23 02:30Core Viewpoint - The stock of Ailis has experienced a significant increase of 78.14% year-to-date, despite a recent decline of 2.02% on September 23, 2023, indicating volatility in the market [1]. Financial Performance - For the first half of 2025, Ailis reported a revenue of 2.374 billion yuan, representing a year-on-year growth of 50.57% [2]. - The net profit attributable to shareholders for the same period was 1.051 billion yuan, showing a year-on-year increase of 60.22% [2]. Shareholder Information - As of June 30, 2025, Ailis had 13,000 shareholders, an increase of 3.61% from the previous period [2]. - The average number of circulating shares per shareholder was 34,578, which decreased by 3.48% compared to the previous period [2]. Dividend Distribution - Ailis has distributed a total of 653 million yuan in dividends since its A-share listing [3]. Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders included notable entities such as Huaxia SSE Sci-Tech Innovation Board 50 ETF, which increased its holdings by 1.3199 million shares to 12.4209 million shares [3]. - Hong Kong Central Clearing Limited reduced its holdings by 2.4609 million shares to 10.3778 million shares [3]. - New institutional shareholder, China Europe Medical Health Mixed A, entered the top ten with a holding of 9.1525 million shares [3].